Historically, adverse effects of medicines have been identified through spontaneous adverse reaction reporting followed by ‘ad hoc’ studies designed to quantify risk.  Widespread access to large linked routinely collected databases made this process more efficient, but it often takes years for separate research groups to collectively address an important safety question. In response, several collaborations have formed internationally that enable simultaneous analyses of data bases in multiple jurisdictions. The Canadian Network for Observational Drug Effect Studies was established in 2011 and since then 120 researchers in 8 provinces have performed over 120 analyses of large population data-bases from 10 jurisdictions. This work has confirmed specific risks or demonstrated relative safety of several major drug classes, including anti-microbials, anti-psychotics, incretin-based drugs, opioids, statins, retinoids, acid pump inhibitors, anticoagulants, biologics and anti-emetics. Distributed analysis ensures that a common analytical protocol is applied to multiple data-bases, comprising a possible total population of 100 million or more. A Methods team ensures consistency of work across sites and monitors factors that might introduce bias into treatment effect estimates.  A COI management policy limits the roles of individuals who have any links to manufacturers and a knowledge translation group.

Speaker Bio

David HenryDavid Henry , (Bond University)

Is a Professor at the Institute for Evidence-Based Healthcare at Bond University. He also holds conjoint positions at the University of Newcastle, University of Melbourne and an Emeritus Chair at the University of Toronto. He also worked as an internal medicine specialist for many years after completing training in clinical pharmacology and gastroenterology. His research has been mainly in the fields of pharmacoepidemiology and WHO medicines policies in both high- and low-income countries. He was active in the development of drug subsidization programs in Australia and South Africa.

About Seminar Series

The School of Pharmacy Seminar Series involves regular formal presentations of high-quality scholarly work with broad appeal.

The wider School community is invited to attend, including academic and professional staff, special guests, visitors, as well as HDR, postgraduate, masters and honours students.

Seminars are held on Fridays from 12pm–1pm in room 5034 in the Pharmacy Australia Centre of Excellence, 20 Cornwall St Woolloongabba (next to TRI and the PA Hospital).

Confirmed 2022 seminars



12-1pm, Friday 1st April (PACE R5034 and Zoom)

Dr Ran Wang, Mater Research Institute, UQ

12-1pm, Friday 22nd April (Zoom Only)

Dr Joanna Harnett, School of Pharmacy, The University of Sydney

12-1pm, Friday 29th April (PACE R5034 and Zoom)Dr Iman Azimi, Lecturer in Pharmaceutical Science, University of Tasmania

12-1pm, Friday 6th May (PACE R5034 and Zoom)

Dr Larisa Labzin, Institute of Molecular Bioscience, UQ

12-1pm, Friday 20th May (PACE R5034 and Zoom)

Prof Nina Barnett, Consultant Pharmacist,

Visiting Professor Kingston University, UK, London

11am-12pm, Friday 27th May (Zoom only)

Prof Terry Hebert, Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada

12-1pm, Friday 3rd June (PACE R5034 and Zoom)

A/Prof Joy Wolfram, School of Chemical Engineering, UQ

12-1pm, Friday 17th June (PACE R5034 and Zoom)

Dr Rink-Jan Lohman, School of Pharmacy, UQ and

Dr Karnaker Reddy Tupally, School of Pharmacy, UQ

12-1pm, Friday 1st July (PACE R5034 and Zoom)

Dr Khay Fong, School of Environmental Life Sciences, University of Newcastle


Pharmacy Australia Centre of Excellence, 20 Cornwall St, Woolloongabba